FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

12 letters match. Newest first.

  1. Pine Pharmaceuticals, LLC

    FDA cited outsourcing facility Pine Pharmaceuticals in Tonawanda, NY, for insanitary sterile compounding conditions and CGMP failures after a November 2025 inspection.

    High risk
  2. Janssen Vaccines Corp., A Johnson & Johnson Company

    FDA warned Janssen Vaccines over inadequate investigations of stopper complaints and missed regulatory notifications for its injection drug.

    Medium
  3. Everlaan Organics, Inc. dba Maple Organics

    FDA warns Maple Organics over OTC drug CGMP failures, unapproved new drugs, and misbranding.

    High risk
  4. Baldwin Richardson Foods Pennsauken, LLC

    FDA warned Baldwin Richardson Foods Pennsauken of serious low-acid canned food violations after finding microbial growth and process-control failures in aseptic non-dairy beverages.

    High risk
  5. Excelvision Fareva

    Excelvision Fareva, a sterile drug manufacturer, was cited for inadequate mold/black-speck complaint investigations and aseptic contamination controls.

    High risk
  6. BPI Labs, LLC

    BPI Labs distributes unapproved Epinephrine Chloride Nasal Solution in a vial FDA says can be mistaken for injectable epinephrine.

    High risk
  7. Right Value Drug Stores, LLC dba Carie Boyd Pharmaceuticals

    FDA warned outsourcing facility Carie Boyd Pharmaceuticals in Irving, TX that sterile drug production had airflow, media fill and contamination control failures.

    High risk
  8. Aqualex Co., Ltd.

    Aqualex, a Korean contract manufacturer, was cited for manufacturing failures and an unapproved OTC sunscreen with misleading labeling.

    High risk
  9. Delsam Pharma LLC

    Delsam Pharma distributed non-sterile, contaminated artificial tears and eye ointment made by its contract manufacturer, FDA found.

    High risk
  10. Global Pharma Healthcare Private Limited

    FDA warned Global Pharma Healthcare that non-sterile artificial tears and eye ointment from its India plant were tied to a Pseudomonas outbreak with four deaths.

    High risk
  11. Sagent Pharmaceuticals, Inc.

    FDA found SterRx, acquired by Sagent, made sterile drugs under conditions that risked contamination and lacked sterility assurance.

    High risk
  12. Nephron SC Inc.

    Nephron SC's sterile drug manufacturing had unresolved cross-contamination and microbial contamination, making its drugs adulterated.

    High risk